AnalystsEva Fortea VerdejoEva Fortea Verdejo's Stock Forecasts
AnalystsEva Fortea Verdejo
Sectors:
Industries:
Analyst Ranking
Top 38%
#1852 out of 4929 analysts
Average Return
+4.24%
Win Rate
62%8 out of 13
Risk vs Reward
Poor
Good
Eva Fortea Verdejo's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Iteos Therapeutics IncITOS | +46.86% | $6.85 | $10.06 | 2025-04-29 - 2025-05-28 | Strong Buy |
Iteos Therapeutics IncITOS | +41.79% | $7.10 | $10.06 | 2025-03-06 - 2025-05-28 | Strong Buy |
Iteos Therapeutics IncITOS | +39.34% | $7.22 | $10.06 | 2024-12-19 - 2025-05-28 | Strong Buy |
Kiniksa Pharmaceuticals International PLCKNSA | +37.70% | $20.08 | $27.65 | 2024-05-03 - 2025-05-02 | Strong Buy |
Iteos Therapeutics IncITOS | +32.37% | $7.60 | $10.06 | 2025-05-14 - 2025-05-28 | Strong Buy |
Eva Fortea Verdejo Analyst Color
Get additional color on Eva Fortea Verdejo's coverage of popular stocks
Eva Fortea Verdejo's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Ideaya Biosciences IncIDYA | 1 | Strong Buy | $44.00 | +99.10% | Initiates Coverage On | 10 days ago |
Iteos Therapeutics IncITOS | 6 | Hold | $12.00 | +17.88% | Downgrades | a month ago |
Bicara Therapeutics IncBCAX | 2 | Hold | $8.00 | -11.41% | Upgrades | a month ago |
Merus NvMRUS | 1 | Strong Buy | $89.00 | +65.37% | Maintains | 2 months ago |
Arcus Biosciences IncRCUS | 2 | Strong Buy | $26.00 | +206.97% | Maintains | 2 months ago |
Xencor IncXNCR | 2 | Strong Buy | $33.00 | +291.92% | Maintains | 4 months ago |
Kiniksa Pharmaceuticals International PLCKNSA | 1 | Strong Buy | $34.00 | N/A | Initiates Coverage On | a year ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.